

# “Rheum to Improve”: Quality Improvement in Outpatient Rheumatology

Shirley L. Chow and Kaveh G. Shojania

**ABSTRACT.** The commitment to improve care processes and patient outcomes is a professional mandate for clinicians and is also seen as an operational priority for institutions. Quality improvement now figures in the accreditation of training programs, specialty examinations, and hospital scorecards. Rheumatologists have traditionally focused primarily on quality problems such as guideline adherence; however, improvement goals should also include other aspects of care that are helpful to patients and are professionally rewarding for practitioners. This review makes use of improvement projects in outlining tangible tools rheumatologists can use to resolve quality concerns in their practices. (First Release July 1 2017; J Rheumatol 2017;44:1304–10; doi:10.3899/jrheum.161053)

*Key Indexing Terms:*

QUALITY IMPROVEMENT  
VACCINATION

PRACTICE GUIDELINES  
REFERRAL AND CONSULTATION

Improving processes of care and patient outcomes is a mandate for all individuals and institutions in medicine<sup>1,2</sup>. Quality improvement (QI) is now involved in the accreditation of residency programs<sup>3,4</sup>, maintenance of certification<sup>5,6</sup>, hospital scorecards, and strategic plans<sup>7</sup>.

Widespread attention to healthcare quality began with the release of *To Err is Human*<sup>8</sup>. This Institute of Medicine (IOM) report identified the interest of the public, clinicians, and decision makers, with its focus on morbidity and mortality from medical error. Capitalizing on this interest, the IOM then released *Crossing the Quality Chasm*<sup>9</sup>, which addressed quality problems more broadly. The second report characterized quality in terms of 6 constituent domains: safety, effectiveness, patient-centeredness, timeliness, efficiency, and equity (Table 1)<sup>9,10,11,12,13,14,15,16,17,18</sup>.

Rheumatologists traditionally focus on quality problems related to effectiveness (e.g., guideline adherence) so it may seem daunting to add QI targets from the other domains listed in Table 1; however, doing so will not only help patients, but also improve the care experience for clinicians (e.g., improving clinic flow). Some domains also reinforce each other for a rewarding effect: engaging patients in shared decision making regarding treatment decisions

(patient-centeredness) may improve medication adherence (effectiveness). Often guideline adherence does not fall solely in the quality domain of effectiveness, but may also lead to improvement in other areas, such as safety.

Quality indicators to measure and improve performance have proliferated in both adult<sup>19,20,21</sup> and pediatric rheumatology<sup>22,23</sup>. The American College of Rheumatology has introduced a quality-reporting system for health practitioners called the Rheumatology Informatics System for Effectiveness (RISE)<sup>24,25</sup>. RISE interfaces with electronic health records to produce performance reports that rheumatologists can use to measure quality and facilitate compliance with new payment models and evolving certification requirements.

But quality indicators and performance reports do not in themselves lead to improvement. We need both methods for understanding the basis for quality problems and pragmatic tools for addressing them. Our paper illustrates how rheumatologists can use these tools for rapid-cycle change to address a variety of quality problems in their practice.

## The Model for Improvement

Though not the only approach to QI, the Model for Improvement has broad appeal because of its simplicity and practicality. It combines 3 questions with the Plan-Do-Study-Act (PDSA) cycle to guide specific improvement activities, as seen in Figure 1<sup>26,27</sup>. We used 2 example projects to illustrate the Model for Improvement and 3 other common QI tools: Pareto analysis, the fishbone diagram, and run charts (a glossary of these and other key terms appears in the Supplementary Data, available with the online version of this article).

**Case 1 Example: Increasing Access to Rheumatology Care**  
*Question 1: What are we trying to accomplish?* A common

*From the Department of Medicine, Sunnybrook Health Sciences Centre; University of Toronto, Toronto, Ontario, Canada.*

*S.L. Chow, Assistant Professor, MD, FRCPC, MSc, Quality Improvement and Patient Safety, Department of Medicine, Sunnybrook Health Sciences Centre, and the University of Toronto; K.G. Shojania, MD, Professor, Department of Medicine, Sunnybrook Health Sciences Centre, and the University of Toronto.*

*Address correspondence to Dr. S.L. Chow, Division of Rheumatology, Room M1400, Sunnybrook Health Sciences Centre, 2075 Bayview Ave., Toronto, Ontario M4N 3M5, Canada. E-mail: Shirley.Chow@sunnybrook.ca*  
*Accepted for publication April 5, 2017.*

Table 1. The domains of quality improvement and examples in rheumatology.

Domains of Quality Improvement	Definitions of the Different Quality Improvement Domains <sup>9</sup>	Examples of Quality Improvement Problems Seen in Rheumatology that Address these Domains
1. Patient safety	Avoiding harm to patients from the care that is intended to help them.	Use of folic acid supplementation to prevent methotrexate-induced transaminitis in patients with RA <sup>10</sup> . Screening for tuberculosis in patients considering biologics.
2. Patient-centered care	Providing care that is respectful of and responsive to individual patient preferences, needs, and values, and ensuring that patient values guide all clinical decisions.	Shared decision making, support for self-management, involvement of family and friends, and facilitating emotional support represent intrinsic goals for patients; they may also help promote other quality-of-care goals (e.g. enhancing medication adherence in established RA) <sup>11</sup> .
3. Effective care	Providing services based on scientific knowledge to all who could benefit and refraining from providing services to those not likely to benefit (avoiding underuse and misuse, respectively).	All patients with RA should have their disease activity assessed and monitored over time <sup>12</sup> .
4. Timely care	Reducing waits and sometimes harmful delays for both those who receive and those who give care.	Long wait times to access rheumatology care improved by central referral and triage service <sup>13</sup> .
5. Efficient care	Avoiding waste, including waste of equipment, supplies, ideas, and energy.	Choosing Wisely: An intervention to reduce unnecessary antinuclear antibody testing <sup>14</sup> . Using FRAX to screen for fracture risk may reduce unnecessary bone mineral density testing <sup>15</sup> .
6. Equitable care	Providing care that does not vary in quality because of personal characteristics such as sex, ethnicity, geographic location, and socioeconomic status.	Patients' access to biological therapy for chronic inflammatory conditions varies based on access to care <sup>16</sup> . Emerging biosimilars may compensate for inequities <sup>17</sup> . Limited access to care and specialist rheumatology care for First Nations patients in Canada <sup>18</sup> .

RA: rheumatoid arthritis; FRAX: World Health Organization fracture risk assessment tool.




Figure 1. The model for improvement<sup>26,27</sup>. Adapted from Berwick, BMJ 1996;312:619-22; with permission.

quality problem is excessive wait times for new appointments. The Model for Improvement stipulates a measurable accomplishment in a specific time frame. “We plan to improve access” specifies nothing concrete. A good aim statement should be “SMART”: Specific (What are we trying

to improve?), Measurable (By how much will we improve it?), Applicable, Realistic, and Timely (By when will this occur?). For instance, “We will reduce the median wait time for new appointments by 50% over the next 12 months.”

Sometimes we need to revise the aim statement as the

project unfolds. Once we understand the full range of contributing causes, we recognize that we have no control over some important aspects of the problem. For example, perhaps as the access project unfolds it becomes clear that wait times for patients are not as important as the delays in seeing urgent referrals. A prudent solution would be to revise the aim to: “By this time next year, we will consistently see 90% of urgent referrals within 4 weeks.”

The idea is to start with a concrete aim, including a specific measure of success, the amount one plans to improve that measure, and the timeline to do so, but also to recognize that the specifics may evolve as the target problem is better understood.

*Question 2: How will I know if a change leads to improvement?* Improvement projects typically use 3 types of measures: outcome, process, and balancing measures<sup>28</sup>. Outcomes reflect what happens to patients — the rate at which they received guideline-concordant care (effectiveness), or as in our example, wait times for urgent referrals. Process measures, by contrast, characterize the degree to which an improvement is playing out as intended. Are clinicians using the new order set or referral form? Are they reading the performance report cards? Think of process measures such as compliance in a clinical trial. Evaluating efficacy requires knowing whether patients took the study drug. Similarly, to determine whether our improvement idea works, we need to know that it was implemented successfully — that clinicians or patients “took the pill.” Finally, balancing measures assess the emergence of undesirable consequences. A project aiming to reduce length of hospital stay might monitor 30-day readmissions because we would not want to reduce length of stay by prematurely discharging patients who must then return to the hospital.

For our example, the proportion of urgent referrals seen within 4 weeks constitutes the outcome. As a balancing measure, we would track the proportion of nonurgent referrals waiting more than 3 months to ensure this did not increase as an unintended consequence of our efforts to see urgent patients within 4 weeks. Process measures depend on what “change idea” or intervention we think might result in improvement. A hypothetical change idea could be to implement a new referral form to facilitate identifying urgent referrals. An early process measure might track the proportion of referrals using the new form. Once usage reaches a reasonable level, we may need to audit the accuracy of the information related to assessing urgency.

References to multiple process and balancing measures may raise concerns over measurement burden. Importantly, frequent small sample sizes (e.g., 10 patients) suffice for monitoring these key steps in the change processes<sup>29</sup>. For instance, in the early stages of our project, we want to know whether clinicians are using a new referral form 90% of the time. Auditing 10 consecutive referrals finds that the new form is used in only 5 of them. The 95% CI for this proportion of 50% ranges from 31% to 86%. A CI this wide

would serve little purpose in clinical research. No one wants to say that a treatment works somewhere between 31% and 86% of the time, but for our improvement project, this small sample size suffices to show we have not yet achieved 90% usage, so that further refinements to the referral form (or further efforts to promote its use) are required<sup>29</sup>.

*Question 3: What changes might result in improvement?* Identifying candidate improvements (“change ideas”) that will bring about the project’s aim constitutes the most difficult step. Some ideas can be discarded based on common sense. For example, working harder to see more patients represents a quick fix, but not a sustainable one. Hiring more rheumatologists would help, but might not be feasible in the desired timeline. Moreover, after some initial reductions in wait times, the problem may reappear as the new clinicians’ panel sizes grow.

In general, rather than brainstorming solutions, start with understanding why the problem exists. Even experienced clinicians should not underestimate the myriad of contributing factors to a given quality problem. Some may indeed be immediately apparent, but identifying others requires a systematic approach to diagnosis. Two commonly encountered tools for characterizing quality problems include the Ishikawa (or “fishbone”) diagram, which will be described later, and the Pareto analysis. We do not discuss process mapping, which is involved in many efficiency projects<sup>30</sup>.

A Pareto analysis helps focus on causes of the target problem with greatest potential effect. For instance, a restaurant owner notes that complaints about service quality, price, and noise account for 80% of all negative online reviews. The owner reasonably decides to target those 3 categories, not wasting efforts on the multiple other complaints that account for only a small percentage of negative reviews. Returning to our example, we realize that inappropriate referrals substantially contribute to the problematic wait time (1 report judged that 40% of referrals as inappropriate<sup>31</sup>). We conduct a Pareto analysis to identify the most common types of inappropriate referrals.

We screen referrals that were received but not scheduled, as well as patients seen just once with no followup, to identify patients whom we believe did not require a rheumatologist. Three categories account for 85% of inappropriate referrals — referrals better directed to another specialty, borderline anti-nuclear antibody results with no relevant symptoms, and patients with fibromyalgia already assessed by another rheumatologist and receiving appropriate treatment yet seeking another opinion. We could develop standard letters to send back to referring doctors for each of these referral types. Even if each required a different approach, the Pareto analysis (often accompanied by a simple bar chart showing the cumulative percentage accounted for by each category) efficiently highlights the minority of issues that cause most problems.

*Step 4: PDSA cycles.* After asking the 3 crucial questions, we can start testing changes. PDSA cycles (Figure 1) amount to

inductive learning—iterative cycles of change, measurement, and reflection on the consequences of the change.

For our first change idea, we modify the referral form to better identify the reason for referral and ensure all necessary tests were provided. After several weeks in a row where at least 90% of new referrals used the new form, we audit a small sample for accuracy and realize that sometimes the reason cited was not entirely correct. While discussing this with the clinic secretary, it also becomes apparent that the new referral form has generated frequent requests back to referring doctors for more information. Rapid cycle improvement means testing change ideas quickly, sometimes refining them in successive cycles, but other times abandoning them. Changing the referral form may not work for all referrals and the assistant may become overwhelmed. Do not rush to a solution.

Sometimes in the process of analyzing 1 change idea, a new one emerges. The clinic has hired several advanced practice and extended role practice (AP/ERP) professionals. These include physiotherapists, occupational therapists, registered nurses, and physician assistants who have received advanced training, skills, and experience in the care of people with arthritis<sup>32,33</sup>. Through multiple iterative modifications to the process for triage, patient assessment, test ordering, and facilitating system navigation of referred patients<sup>34,35</sup>, we incorporate the AP/ERP into a different model of care that drops the median wait times. Different evaluations have shown improved wait times for patients with inflammatory arthritis<sup>36</sup>, including 1 with a dropped median reduction from 39 days to 22 days<sup>37</sup>.

Subsequent PDSA might modify the scheduling process, but how do we track our improvements and monitor for any unintended consequences? Run charts provide effective tools for displaying the data over time, with formal rules for detecting statistically significant changes<sup>38</sup>. These rules share the same conventional  $p = 0.05$  threshold for rejecting null hypotheses that guide clinical research. For instance, under normal circumstances, wait times should fluctuate randomly, with a 50-50 chance that the median number of days to clinic appointment in a given month is above or below the median. Thus, if 6 successive data points fall below the median (from before the change), it resembles tossing a coin on heads 6× in a row, an event that has a probability of about 1%. When this occurs, as it clearly does in this case (Figure 2), we can infer that a statistically significant change has occurred. One busy academic rheumatology office lowered its third available appointment (a common wait time metric) from 60 days to < 2 days by creating space<sup>39</sup>. Cancellations fell and patient satisfaction measures improved significantly. Financial performance improved as well.

This project successfully decreased median wait times for urgent patients through multiple interventions: a change in scheduling, incorporating an AP/ERP, and using a triage form (though in this case, this was the least robust change).

Successful projects usually involve multifaceted interventions, consistent with the idea that several factors contribute to most QI problems, as highlighted by the fishbone diagram in the next example.

### Case 2 Example: Increasing Vaccinations in Immunosuppressed Patients

Given the high risk of influenza and its complications in patients with autoimmune rheumatic diseases<sup>40,41</sup>, guidelines recommend that all patients with rheumatoid arthritis receive the flu shot<sup>42</sup>. However, an audit of rheumatology patients revealed a vaccination rate of only 50%<sup>43</sup>. In a practice audit, one of us (SC) observed a similarly low vaccination rate of 40%. Patients were variably asked about vaccination status, and immunization history was not routinely documented. While the previous example involved a pastiche of projects from the literature, one of us (SC) undertook this second example project with several colleagues. We aimed to increase the proportion of patients with autoimmune rheumatic disease who received the flu shot to at least 80% in 1 year.

Like many undertaking improvement projects, we made the mistake of jumping to a solution<sup>44</sup> by assuming that simply reminding patients to get the flu shot would solve the problem. We created a reminder to prompt clinicians to tell their patients about vaccination. An audit a few months into the project revealed no increase in uptake. In QI, it is better to understand the problem and complete small tests of change, rather than just deciding on a change and plowing ahead.

A fishbone diagram provides a framework for considering the various possible variables influencing a problem, with categories for patient factors (e.g., beliefs and expectations), provider factors (time, knowledge, attitudes), equipment problems (e.g., usability and maintenance), and organizational characteristics, including staffing and infrastructure, but also culture. Figure 3 shows our fishbone diagram for barriers to obtaining the flu shot. These barriers were identified from the literature, local data collection, and reflection by an interdisciplinary group allowing for more varied perspectives. We asked patients about their views because they often provide crucial information.

Our first PDSA cycle focused on standardizing the process for documenting vaccination status in immunosuppressed patients. Obtaining an up-to-date immunization status by sending a template letter to family doctors helped to document this. Next, we surveyed patients to identify reasons for not receiving immunization. The most common reasons included not knowing about the need for vaccination, forgetfulness (for patients and their providers), and the inconvenience of an extra appointment just to receive the flu shot. It is important to drill down to understand why each of these causes exist. Identifying the reasons informs creating a change strategy. To address these challenges, we needed an intervention that not only increased awareness among patients and physicians, but also improved access to the flu shot.




Figure 2. Run chart of wait times for urgent patients. The run chart shows the median number of days each month between receipt of an urgent referral and seeing the patient in clinic. An obvious reduction in wait times takes place between June and August. Wait times initially drop with pre-appointment screening; however, the improvement was not sustained. Subsequently changing the model of care and introducing an AP/ERP in pre-appointment screening, assessment, and management significantly dropped the median wait time. AP: advanced practice; ERP: extended role practitioner; P: plan; D: do; A: act; S: study.




Figure 3. Fishbone diagram of barriers to flu vaccination. This diagram works by forcing one to consider all the different potential categories of problems and to assemble all plausible causes within each category. The square boxes then indicate the ones that play important roles. This determination can come from the literature, local data collection, and reflection, but in the case of the latter, one should always include multidisciplinary perspectives and patients.

Our next PDSA cycle created a patient pamphlet highlighting the risks of the flu and benefits of immunization in immunosuppressed patients. These different colored pamphlets placed in examination rooms reminded physicians to ask about vaccination and included a walking map to the hospital pharmacy where patients could not only pick up their medications, but also receive the flu shot.

We made some progress in terms of informing patients and physicians about the need for flu shots. However, providers often did not distribute pamphlets. The flyer was too small to read, and it was easy to overlook immunosuppressed patients during busy clinics. For the next PDSA cycle, the pamphlets were made more patient-friendly with larger graphics and fonts. We also created neon stickers to be placed on the disease-modifying antirheumatic drug prescriptions to remind pharmacists to administer the flu shot when they renewed medications.

Following these refinements, 60%–90% of our patients received the pamphlets or sticker (process measure), and 65% of immunosuppressed individuals obtained the flu shot (project outcome measure), up from 40% prior to the project. Although we did not meet our goal of > 80% at the end of the season, we did achieve a relative improvement of 60%. Similar to clinical research, modest improvements are common and one should not become discouraged. Additional interventions may move the needle further since QI almost always requires multifaceted changes. If an intervention succeeds in achieving change, it is vital to plan to sustain and spread improvements. Ensuring that the improved vaccination rates are maintained and shared with other similar organizations can be achieved through different methods such as having a supportive management structure, building a culture of improvement, and deeply engaging staff<sup>45</sup>.

### Final Thoughts

PDSA cycles provide a practical approach for learning and informing action, but learning is rarely linear because each cycle can reveal other issues that need to be addressed to achieve the improvement goal<sup>46</sup>. For larger scale projects, success typically requires investment in participant engagement, management support, alignment of financial incentives, and additional methodological expertise<sup>47</sup>. For many smaller projects in a clinic, however, success can come with application of the Model for Improvement and basic QI tools such as the fishbone diagram, Pareto analysis, and run charts as illustrated in the examples presented. Online tutorials provide further guidance for using tools<sup>48</sup>. A recent review walks readers through an easy-to-follow PDSA project, highlighting the easily understood, practical design of each step, yet the powerful effect the methodology produced as a whole<sup>49</sup>.

Like all physicians in contemporary practice, rheumatologists must address quality problems. Doing so falls within our professional responsibility because external bodies increasingly hold us accountable to performance expecta-

tions, a trend that will only accelerate. Beyond these incentives, in our experience and those of many colleagues and trainees learning QI methods in recent years, successful improvement projects deliver an intrinsic satisfaction associated with solving problems that frustrate efforts to deliver high-quality care. These projects also bring a special type of professional satisfaction through improving the care of many patients. Further, just as we enjoy exchanging clinical experiences with colleagues, sharing successful redesigns also brings a particular professional pleasure.

### ONLINE SUPPLEMENT

Supplementary material accompanies the online version of this article.

### REFERENCES

1. Berwick DM. The question of improvement. *JAMA* 2012;307:2093-4.
2. Batalden PB, Davidoff F. What is “quality improvement” and how can it transform healthcare? *Qual Saf Health Care* 2007;16:2-3.
3. Accreditation Council for Graduate Medical Education. ACGME common program requirements. [Internet. Accessed April 11, 2017.] Available from: [www.acgme.org/Portals/0/PFAssets/ProgramRequirements/CPRs\\_07012016.pdf](http://www.acgme.org/Portals/0/PFAssets/ProgramRequirements/CPRs_07012016.pdf)
4. Wong BM, Ackroyd-Stolarz S, Bukowskyj M, Calder L, Ginzburg A, Microys S, et al. The CanMEDS 2015 patient safety and quality improvement expert working group report. [Internet. Accessed April 7, 2017.] Ottawa: The Royal College of Physicians and Surgeons of Canada; 2014. Available from: [www.royalcollege.ca/portal/page/portal/rc/common/documents/canmeds/framework/patient\\_safety\\_ewg\\_report\\_e.pdf](http://www.royalcollege.ca/portal/page/portal/rc/common/documents/canmeds/framework/patient_safety_ewg_report_e.pdf)
5. Royal College of Physicians and Surgeons of Canada. The maintenance of certification program. Section 3 credits. [Internet. Accessed April 7, 2017.] Available from: [www.royalcollege.ca/rcsite/cpd/moc-program/about-moc-program-e](http://www.royalcollege.ca/rcsite/cpd/moc-program/about-moc-program-e)
6. The American Board of Internal Medicine. Earning Maintenance of Certification Points – Practice assessment. [Internet. Accessed April 7, 2017.] Available from: [www.abim.org/maintenance-of-certification/earning-points/practice-assessment.aspx](http://www.abim.org/maintenance-of-certification/earning-points/practice-assessment.aspx)
7. Weiss KB, Bagian JP, Nasca TJ. The clinical learning environment: the foundation of graduate medical education. *JAMA* 2013;309:1687-8.
8. Kohn LT, Corrigan JM, Donaldson MS. To err is human: building a safer health system. Washington: National Academy Press; 2000.
9. Institute of Medicine. Crossing the quality chasm: a new health system for the 21st century. [Internet. Accessed April 7, 2017.] Washington: National Academy Press; 2001. Available from: [www.nationalacademies.org/hmd/~/media/Files/Report%20Files/2001/Crossing-the-Quality-Chasm/Quality%20Chasm%202001%20%20report%20brief.pdf](http://www.nationalacademies.org/hmd/~/media/Files/Report%20Files/2001/Crossing-the-Quality-Chasm/Quality%20Chasm%202001%20%20report%20brief.pdf)
10. Suzuki Y, Uehara R, Tajima C, Noguchi A, Ide M, Ichikawa Y, et al. Elevation of serum hepatic aminotransferases during treatment of rheumatoid arthritis with low-dose methotrexate. Risk factors and response to folic acid. *Scand J Rheumatol* 1999;28:273-81.
11. Voshaar MJ, Nota I, van de Laar MA, van den Bemt BJ. Patient-centred care in established rheumatoid arthritis. *Best Pract Res Clin Rheumatol* 2015;29:643-63.
12. Anderson E, Bajaj P, Raghavan S, Patnaik A, Roppelt H. Assessment of American College of Rheumatology-endorsed quality indicators in rheumatoid arthritis patients: a quality improvement initiative. *J Clin Rheumatol* 2016;22:63-7.
13. Hazlewood GS, Barr SG, Lopatina E, Marshall DA, Lupton TL, Fritzler MJ, et al. Improving appropriate access to care with central referral and triage in rheumatology. *Arthritis Care Res* 2016;68:1547-53.
14. Lesuis N, Hulscher ME, Piek E, Demirel H, van der

- Laan-Baalbergen N, Meek I, et al. Choosing wisely in daily practice: an intervention study on antinuclear antibody testing by rheumatologists. *Arthritis Care Res* 2016;68:562-9.
15. Edwards FD, Grover ML, Cook CB, Chang YH. Use of FRAX as a determinant for risk-based osteoporosis screening may decrease unnecessary testing while improving the odds of identifying treatment candidates. *Womens Health Issues* 2014;24:629-34.
  16. Gulácsi L, Rencz F, Poór G, Szekanecz Z, Brodszky V, Baji P, et al. Patients' access to biological therapy in chronic inflammatory conditions; per capita GDP does not explain the intercountry differences. *Ann Rheum Dis* 2016;75:942-3.
  17. Dörner T, Strand V, Cornes P, Gonçalves J, Gulácsi L, Kay J, et al. The changing landscape of biosimilars in rheumatology. *Ann Rheum Dis* 2016;75:974-82.
  18. Barnabe C, Jones CA, Bernatsky S, Peschken CA, Voaklander D, Homik J, et al. Inflammatory arthritis prevalence and health services use in the First Nations and non-First Nations populations of Alberta, Canada. *Arthritis Care Res* 2017;69:467-74.
  19. Barber CE, Marshall DA, Mosher DP, Akhavan P, Tucker L, Houghton K, et al; Arthritis Alliance of Canada Performance Measurement Development Panel. Development of system-level performance measures for evaluation of models of care for inflammatory arthritis in Canada. *J Rheumatol* 2016;43:530-40.
  20. American College of Rheumatology. ACR endorsed measures. [Internet. April 7, 2017.] Available from: [www.rheumatology.org/Practice-Quality/Clinical-Support/Quality-Measurement/ACR-Endorsed-Measures](http://www.rheumatology.org/Practice-Quality/Clinical-Support/Quality-Measurement/ACR-Endorsed-Measures)
  21. MacLean CH, Saag KG, Solomon DH, Morton SC, Sampsel S, Klippel JH. Measuring quality in arthritis care: methods for developing the Arthritis Foundation's quality indicator set. *Arthritis Rheum* 2004;51:193-202.
  22. Lovell DJ, Passo MH, Beukelman T, Bowyer SL, Gottlieb BS, Henrickson M, et al. Measuring process of arthritis care: a proposed set of quality measures for the process of care in juvenile idiopathic arthritis. *Arthritis Care Res* 2011;63:10-6.
  23. Harris JG, Bingham CA, Morgan EM. Improving care delivery and outcomes in pediatric rheumatic diseases. *Curr Opin Rheumatol* 2016;28:110-6.
  24. Desai SP, Yazdany J. Quality measurement and improvement in rheumatology: rheumatoid arthritis as a case study. *Arthritis Rheum* 2011;63:3649-60.
  25. American College of Rheumatology. RISE (qualified clinical data registry). [Internet. Accessed April 17, 2017.] Available from: [www.rheumatology.org/I-Am-A/Rheumatologist/Registries/RISE](http://www.rheumatology.org/I-Am-A/Rheumatologist/Registries/RISE)
  26. Langley GL, Moen R, Nolan KM, Nolan TW, Norman CL, Provost LP. *The improvement guide: a practical approach to enhancing organizational performance*, 2nd edition. San Francisco: Jossey-Bass Publishers; 2009.
  27. Berwick DM. A primer on leading the improvement of systems. *BMJ* 1996;312:619-22.
  28. Institute for Healthcare Improvement. Science of improvement: establishing measures. [Internet. Accessed April 7, 2017.] Available from: [www.ihl.org/resources/Pages/HowtoImprove/ScienceofImprovementEstablishingMeasures.aspx](http://www.ihl.org/resources/Pages/HowtoImprove/ScienceofImprovementEstablishingMeasures.aspx)
  29. Etchells E, Ho M, Shojania KG. Value of small sample sizes in rapid-cycle quality improvement projects. *BMJ Qual Saf* 2016;25:202-6.
  30. Hydes T, Hansi N, Trebble TM. Lean thinking transformation of the unседated upper gastrointestinal endoscopy pathway improves efficiency and is associated with high levels of patient satisfaction. *BMJ Qual Saf* 2012;21:63-9.
  31. Harrington JT, Walsh MB. Pre-appointment management of new patient referrals in rheumatology: a key strategy for improving health care delivery. *Arthritis Rheum* 2001;45:295-300.
  32. Davis AM, MacKay C, Bradley EM. Access to care for people with arthritis: enhancing care across the continuum using advanced practitioners/extended role practitioners. [Internet. Accessed April 11, 2017.] Available from: [www.aceu.ca/pdf/pub5/08-01.pdf](http://www.aceu.ca/pdf/pub5/08-01.pdf)
  33. Landon K, Shupak R, Schneider R, Herold McIlroy J. Development and early evaluation of an inter-professional post-licensure education programme for extended practice roles in arthritis care. *Physiother Can* 2011;63:94-103.
  34. Landon K, Shupak R, Sunstrum-Mann L, Galet D, Schneider R. Leading change in the transformation of arthritis care: development of an inter-professional academic-clinical education training model. *Healthc Q* 2008;11:62-8.
  35. Suter E, Birney A, Charland P, Misfeldt R, Weiss S, Howden JS, et al. Optimizing the interprofessional workforce for centralized intake of patients with osteoarthritis and rheumatoid disease: case study. *Hum Resour Health* 2015;13:41.
  36. Farrer C, Abraham L, Jerome D, Hochman J, Gakhal N. Triage of rheumatology referrals facilitates wait time benchmarks. *J Rheumatol* 2016;43:2064-7.
  37. Passalant LA, Kennedy C, Warmington K, Soever LJ, Landon K, Shupak R, et al. System integration and clinical utilization of the Advanced Clinician Practitioner in Arthritis Care (ACPAC) Program-Trained Extended Role Practitioners in Ontario: a two-year, system-level evaluation. *Healthcare Policy* 2013;8:56-70.
  38. Perla RJ, Provost LP, Murray SK. The run chart: a simple analytical tool for learning from variation in healthcare processes. *BMJ Qual Saf* 2011;20:46-51.
  39. Newman ED, Harrington TM, Oleginski TP, Perruquet JL, McKinley K. "The rheumatologist can see you now": successful implementation of an advanced access model in a rheumatology practice. *Arthritis Rheum* 2004;51:253-7.
  40. Falagas ME, Manta KG, Betsi GI, Pappas G. Infection-related morbidity and mortality in patients with connective tissue diseases: a systematic review. *Clin Rheumatol* 2007;26:663-70.
  41. Blumentals WA, Arreglado A, Napalkov P, Toovey S. Rheumatoid arthritis and the incidence of influenza and influenza-related complications: a retrospective cohort study. *BMC Musculoskelet Disord* 2012;13:158.
  42. Bombardier C, Hazlewood GS, Akhavan P, Schieir O, Dooley A, Haroufi B, et al; Canada Rheumatology Association. Canadian Rheumatology Association recommendations for the pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs: part II safety. *J Rheumatol* 2012;39:1583-602.
  43. Sowden E, Mitchell WS. An audit of influenza and pneumococcal vaccination in rheumatology outpatients. *BMC Musculoskeletal Disorders* 2007;8:58.
  44. Marshall M, de Silva D, Cruickshank L, Shand J, Wei L, Anderson J. What we know about designing an effective improvement intervention (but too often fail to put into practice). *BMJ Qual Saf* 2016 Dec 16 (E-pub ahead of print).
  45. Institute for Healthcare Improvement. How-to guide: sustainability and spread. [Internet. Accessed April 7, 2017.] Available from: [www.ihl.org/resources/Pages/Tools/HowtoGuideSustainabilitySpread.aspx](http://www.ihl.org/resources/Pages/Tools/HowtoGuideSustainabilitySpread.aspx)
  46. Ogrinc G, Shojania KG. Building knowledge, asking questions. *BMJ Qual Saf* 2014;23:265-7.
  47. Reed JE, Card AJ. The problem with Plan-Do-Study-Act cycles. *BMJ Qual Saf* 2016;25:147-52.
  48. Institute for Healthcare Improvement. Run chart tool. [Internet. Accessed April 7, 2017.] Available from: [www.ihl.org/resources/pages/tools/runchart.aspx](http://www.ihl.org/resources/pages/tools/runchart.aspx)
  49. Leis JA, Shojania KG. A primer on PDSA: executing plan-do-study-act cycles in practice, not just in name. *BMJ Qual Saf* 2016 Dec 16 (E-pub ahead of print).